EFCAB6

Summary

EFCAB6 (EF-hand calcium binding domain 6, HGNC:24204) is a protein-coding gene on chromosome 22q13.2-q13.31, encoding EF-hand calcium-binding domain-containing protein 6 (Q5THR3). Negatively regulates the androgen receptor by recruiting histone deacetylase complex, and protein DJ-1 antagonizes this inhibition by abrogation of this complex.

This gene encodes a protein which directly binds the oncogene DJ-1 and androgen receptor to form a ternary complex in cells. This binding protein recruits histone-deacetylase complexes in order to repress transcription activity of androgen receptor. This protein may also play a role in spermatogenesis and fertilization. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 64800 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 306 total
• MANE Select transcript: NM_022785

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24204
Approved symbol	EFCAB6
Name	EF-hand calcium binding domain 6
Location	22q13.2-q13.31
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23588, DJBP, HSCBCIP1, KIAA1672, dJ185D5.1
Ensembl gene	ENSG00000186976
Ensembl biotype	protein_coding
OMIM	619664
Entrez	64800

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 5 protein_coding, 5 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000262726, ENST00000356087, ENST00000396231, ENST00000404038, ENST00000461800, ENST00000468552, ENST00000476600, ENST00000477145, ENST00000483324, ENST00000485142, ENST00000970826, ENST00000970827

RefSeq mRNA: 2 — MANE Select: NM_022785 NM_022785, NM_198856

CCDS: CCDS14049, CCDS14050

Canonical transcript exons

ENST00000262726 — 32 exons

Exon	Start	End
ENSE00000880629	43615826	43615922
ENSE00001297735	43677996	43678163
ENSE00001318450	43683747	43683855
ENSE00001328068	43672246	43672305
ENSE00001408769	43808995	43809131
ENSE00001826388	43812168	43812305
ENSE00003481110	43668872	43669045
ENSE00003483039	43540127	43540357
ENSE00003489212	43576297	43576488
ENSE00003496828	43765305	43765393
ENSE00003498811	43608482	43608600
ENSE00003499001	43626447	43626679
ENSE00003507408	43711475	43711623
ENSE00003510428	43534688	43534872
ENSE00003514663	43735857	43735993
ENSE00003521720	43530815	43530964
ENSE00003537967	43580464	43580659
ENSE00003541154	43554869	43555096
ENSE00003560816	43782180	43782325
ENSE00003598803	43731699	43731811
ENSE00003629487	43537377	43537545
ENSE00003634659	43755766	43755832
ENSE00003635278	43671973	43672133
ENSE00003643343	43772892	43773103
ENSE00003644404	43632105	43632238
ENSE00003647705	43635102	43635216
ENSE00003665184	43687471	43687581
ENSE00003666225	43667104	43667272
ENSE00003675238	43600069	43600263
ENSE00003678953	43590074	43590229
ENSE00003681818	43716848	43716972
ENSE00003841962	43528778	43528975

Expression profiles

Bgee: expression breadth ubiquitous, 182 present calls, max score 95.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.4508 / max 86.1572, expressed in 1032 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
194513	2.0226	935
194512	0.2646	119
194511	0.1543	61
194509	0.0093	4

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	95.11	gold quality
right testis	UBERON:0004534	95.03	gold quality
sperm	CL:0000019	91.98	gold quality
testis	UBERON:0000473	91.82	gold quality
buccal mucosa cell	CL:0002336	90.10	gold quality
right uterine tube	UBERON:0001302	89.58	gold quality
male germ cell	CL:0000015	88.93	gold quality
bronchial epithelial cell	CL:0002328	85.53	gold quality
oocyte	CL:0000023	83.58	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.36	gold quality
epithelium of bronchus	UBERON:0002031	81.99	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	81.12	gold quality
adult organism	UBERON:0007023	81.08	gold quality
bronchus	UBERON:0002185	80.53	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.19	gold quality
secondary oocyte	CL:0000655	74.77	gold quality
adenohypophysis	UBERON:0002196	73.32	gold quality
right lobe of thyroid gland	UBERON:0001119	72.63	gold quality
left lobe of thyroid gland	UBERON:0001120	72.53	gold quality
thyroid gland	UBERON:0002046	72.15	gold quality
pituitary gland	UBERON:0000007	71.87	gold quality
ventricular zone	UBERON:0003053	71.69	gold quality
mucosa of paranasal sinus	UBERON:0005030	70.28	silver quality
calcaneal tendon	UBERON:0003701	70.17	gold quality
colonic epithelium	UBERON:0000397	69.17	gold quality
cortical plate	UBERON:0005343	68.93	gold quality
left ovary	UBERON:0002119	68.73	gold quality
fallopian tube	UBERON:0003889	68.68	gold quality
right adrenal gland cortex	UBERON:0035827	68.61	gold quality
caudate nucleus	UBERON:0001873	68.60	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.52
E-MTAB-7606	no	4.23

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

2 targeting EFCAB6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-1290	99.59	69.90	2079

Literature-anchored findings (GeneRIF, showing 1)

• androgen receptor is positively regulated by DJ-1, which antagonizes the function of negative regulators, including DJBP, a novel DJ-1-binding protein (PMID:12612053)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Efcab6	ENSMUSG00000022441
rattus_norvegicus	Efcab6	ENSRNOG00000011094
drosophila_melanogaster	TpnC47D	FBGN0010423
drosophila_melanogaster	TpnC73F	FBGN0010424
drosophila_melanogaster	TpnC41C	FBGN0013348

Paralogs (5): CAPS (ENSG00000105519), PHF24 (ENSG00000122733), CAPSL (ENSG00000152611), CAPS2 (ENSG00000180881), SPATA21 (ENSG00000187144)

Protein

Protein identifiers

EF-hand calcium-binding domain-containing protein 6 — Q5THR3 (reviewed: Q5THR3)

Alternative names: CAP-binding protein complex-interacting protein 1, DJ-1-binding protein

All UniProt accessions (2): B0QYI5, Q5THR3

UniProt curated annotations — full annotation on UniProt →

Function. Negatively regulates the androgen receptor by recruiting histone deacetylase complex, and protein DJ-1 antagonizes this inhibition by abrogation of this complex. Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating.

Subunit / interactions. Microtubule inner protein component of sperm flagellar doublet microtubules. Binds PARK7. Part of a ternary complex containing PARK7, EFCAB6/DJBP and AR.

Subcellular location. Nucleus. Cytoplasm. Cytoskeleton. Flagellum axoneme.

Tissue specificity. Specifically expressed in the testis.

Isoforms (6)

UniProt ID	Names	Canonical?
Q5THR3-1	1	yes
Q5THR3-2	2, Isoform b
Q5THR3-3	3
Q5THR3-4	4
Q5THR3-6	6
Q5THR3-5	5

RefSeq proteins (2): NP_073622, NP_942153 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR015070	EF_hand_DJBP	Domain
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR052603	EFCB6	Family

Pfam: PF08976, PF13499, PF13833

UniProt features (66 total): domain 17, sequence variant 9, sequence conflict 9, splice variant 8, region of interest 5, helix 5, binding site 4, modified residue 4, compositionally biased region 3, chain 1, strand 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
1WLZ	X-RAY DIFFRACTION	1.6
5D67	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5THR3-F1	69.65	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 754; 756; 758; 765

Post-translational modifications (4): 884, 1290, 1294, 1304

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 67 (showing top): GOBP_CILIUM_MOVEMENT, GOBP_CILIUM_OR_FLAGELLUM_DEPENDENT_CELL_MOTILITY, XU_GH1_EXOGENOUS_TARGETS_UP, MULLIGHAN_MLL_SIGNATURE_2_DN, GOCC_CYTOPLASMIC_REGION, GOCC_MOTILE_CILIUM, chr22q13, GOCC_CYTOPLASMIC_MICROTUBULE, GOCC_CILIUM, MULLIGHAN_MLL_SIGNATURE_1_DN, DODD_NASOPHARYNGEAL_CARCINOMA_DN, HATADA_METHYLATED_IN_LUNG_CANCER_UP, CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN, GOCC_AXONEMAL_MICROTUBULE, GOCC_9PLUS2_MOTILE_CILIUM

GO Biological Process (1): flagellated sperm motility (GO:0030317)

GO Molecular Function (3): calcium ion binding (GO:0005509), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (9): nucleoplasm (GO:0005654), sperm flagellum (GO:0036126), axonemal A tubule inner sheath (GO:0160111), nucleus (GO:0005634), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), cilium (GO:0005929), motile cilium (GO:0031514), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cilium-dependent cell motility	1
cilium movement involved in cell motility	1
sperm motility	1
metal ion binding	1
binding	1
cation binding	1
nuclear lumen	1
9+2 motile cilium	1
A axonemal microtubule	1
axonemal microtubule doublet inner sheath	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
cilium	1

Protein interactions and networks

STRING

1987 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EFCAB6	PARK7	Q99497	909
EFCAB6	AR	P10275	606
EFCAB6	TEKTIP1	A6NCJ1	592
EFCAB6	PIAS2	O75928	577
EFCAB6	CFAP144	A6NL82	471
EFCAB6	TRIM29	Q14134	439
EFCAB6	DRC10	Q96DY2	438
EFCAB6	CTNNB1	P35222	433
EFCAB6	VWA3A	A6NCI4	420
EFCAB6	EFHC2	Q5JST6	420
EFCAB6	MYCBPAP	Q8TBZ2	382
EFCAB6	CFAP161	Q6P656	381
EFCAB6	KRABD5	Q7Z2F6	374
EFCAB6	WBP11	Q9Y2W2	373
EFCAB6	OR4A47	Q6IF82	367

IntAct

1 interactions, top by confidence:

BioGRID (13): EFCAB6 (Affinity Capture-Western), EFCAB6 (Reconstituted Complex), PARK7 (Two-hybrid), EFCAB6 (Affinity Capture-Western), AR (Reconstituted Complex), AR (Affinity Capture-Western), HDAC1 (Affinity Capture-Western), SIN3A (Affinity Capture-Western), EFCAB6 (Two-hybrid), EFCAB6 (Proximity Label-MS), CFL1 (Cross-Linking-MS (XL-MS)), C1QBP (Cross-Linking-MS (XL-MS)), EIF3L (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0JMA8, A0JPI4, A1A535, A1A5P5, A6NMZ2, B7FF67, P34550, Q06A97, Q0P561, Q14156, Q14D04, Q2TAA8, Q3HRN7, Q3HRN8, Q3HRP1, Q3HRP5, Q3MHP3, Q5PPU5, Q5PQS3, Q5QIT3, Q5SPP5, Q5SY68, Q5THR3, Q641A2, Q6R556, Q6ZQ18, Q75LU8, Q7FRS8, Q7Z3E5, Q8BG67, Q8BMD7, Q8C9X1, Q8IGJ0, Q8LAS7, Q8LEM7, Q8NHS4, Q8VZQ4, Q8W475, Q91WD9, Q99P25

Diamond homologs: Q4R8T1, Q5RE62, Q5THR3, Q6P1E8, Q9BXY5, Q09665, B0G159, Q8BUG5, Q9GKR6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

306 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	251
Likely benign	23
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

8011 predictions. Top by Δscore:

Variant	Effect	Δscore
22:43528975:CCT:C	acceptor_loss	1.0000
22:43528976:C:CC	acceptor_gain	1.0000
22:43528977:T:A	acceptor_loss	1.0000
22:43530813:ACCGT:A	donor_gain	1.0000
22:43530814:CCGTC:C	donor_gain	1.0000
22:43530965:C:CC	acceptor_gain	1.0000
22:43534681:AACAT:A	donor_loss	1.0000
22:43534682:ACATA:A	donor_loss	1.0000
22:43534683:CATA:C	donor_loss	1.0000
22:43534684:ATAC:A	donor_loss	1.0000
22:43534685:TA:T	donor_loss	1.0000
22:43534686:A:AG	donor_loss	1.0000
22:43534687:CCAT:C	donor_gain	1.0000
22:43534873:C:CC	acceptor_gain	1.0000
22:43537372:CGAA:C	donor_loss	1.0000
22:43537374:AAC:A	donor_loss	1.0000
22:43537375:AC:A	donor_gain	1.0000
22:43537376:CC:C	donor_gain	1.0000
22:43537376:CCCAG:C	donor_loss	1.0000
22:43537418:T:TA	donor_gain	1.0000
22:43537546:C:CC	acceptor_gain	1.0000
22:43537546:C:G	acceptor_loss	1.0000
22:43554863:TCTTA:T	donor_loss	1.0000
22:43554864:CTTA:C	donor_loss	1.0000
22:43554865:TTA:T	donor_loss	1.0000
22:43554866:TA:T	donor_loss	1.0000
22:43554867:A:C	donor_loss	1.0000
22:43576367:AGTTT:A	donor_gain	1.0000
22:43576393:ATTGT:A	donor_gain	1.0000
22:43576486:TGC:T	acceptor_gain	1.0000

AlphaMissense

10002 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:43528971:A:G	L1463P	0.998
22:43528872:A:G	L1496P	0.997
22:43528875:A:G	F1495S	0.997
22:43530890:C:A	W1436C	0.997
22:43530890:C:G	W1436C	0.997
22:43530892:A:G	W1436R	0.997
22:43530892:A:T	W1436R	0.997
22:43528862:G:C	F1499L	0.996
22:43528862:G:T	F1499L	0.996
22:43528864:A:G	F1499L	0.996
22:43528874:G:C	F1495L	0.996
22:43528874:G:T	F1495L	0.996
22:43528876:A:G	F1495L	0.996
22:43530879:C:G	R1440P	0.996
22:43530822:A:G	F1459S	0.995
22:43530843:C:T	G1452E	0.995
22:43530876:C:G	R1441P	0.995
22:43528974:A:T	V1462D	0.994
22:43530859:C:G	D1447H	0.994
22:43530887:C:A	R1437S	0.994
22:43530887:C:G	R1437S	0.994
22:43534770:A:G	F1384S	0.994
22:43537431:A:G	C1332R	0.994
22:43615866:A:G	L841P	0.994
22:43528872:A:T	L1496H	0.993
22:43528885:A:C	Y1492D	0.993
22:43528950:A:G	L1470P	0.993
22:43528971:A:C	L1463R	0.993
22:43530844:C:A	G1452W	0.993
22:43530859:C:A	D1447Y	0.993

dbSNP variants (sampled 300 via entrez): RS1000015738 (22:43628562 C>T), RS1000023370 (22:43812779 C>T), RS1000030246 (22:43728717 G>A,C), RS1000041757 (22:43672915 G>GA), RS1000065260 (22:43535284 C>A), RS1000067714 (22:43706646 A>G), RS1000080245 (22:43763251 C>T), RS1000082861 (22:43744101 T>C), RS1000087468 (22:43638083 G>A), RS1000097664 (22:43666692 T>TTTTG), RS1000098157 (22:43706449 T>G), RS1000098446 (22:43599341 C>T), RS1000125807 (22:43655274 T>A), RS1000154972 (22:43742935 G>A), RS1000158264 (22:43784929 A>G)

Disease associations

OMIM: gene MIM:619664 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004862_109	Itch intensity from mosquito bite adjusted by bite size	2.000000e-07
GCST004862_110	Itch intensity from mosquito bite adjusted by bite size	2.000000e-07
GCST004862_111	Itch intensity from mosquito bite adjusted by bite size	1.000000e-06
GCST004865_5	Itch intensity from mosquito bite adjusted by bite size	6.000000e-06
GCST008968_1	White coat effect (clinic systolic blood pressure minus ambulatory systolic blood pressure)	9.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0006944	systolic blood pressure change measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
methyleugenol	decreases expression	1
bisphenol A	decreases methylation	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	affects methylation	1
ferrous chloride	decreases expression	1
aflatoxin B2	affects methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
pentanal	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Lipopolysaccharides	increases expression, affects response to substance	1
Methapyrilene	affects methylation	1
N-Nitrosopyrrolidine	decreases expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	decreases expression	1
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	1
S-Nitrosoglutathione	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer